ARAMIS — is darolutamide set to become the ‘third musketeer’ of nmCRPC?

ARAMIS — is darolutamide set to become the ‘third musketeer’ of nmCRPC?ARAMIS — is darolutamide set to become the ‘third musketeer’ of nmCRPC?, Published online: 26 February 2019; doi:10.1038/s41571-019-0191-7ARAMIS — is darolutamide set to become the ‘third musketeer’ of nmCRPC?

Source: Nature Clinical Practice Oncology - February 26, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research